Accredited Business Consolidators Corp., trading as Italian Oven, Inc. is a diversified holding corporation that owns various businesses, parts thereof, or joint ventures which it will assist grow. Visit our website (under construction) at www.accreditedbiz.com for information on our affiliated companies.

IOVE’s authorized common stock is 450,000,000, of which 436,399,500 shares are issued and outstanding. A share issuance moratorium until June 30, 2010, exists that prohibits the company from issuing any additional common shares. 328,018,200 shares are in the public float, and the remaining shares are on file with the transfer agent, of which 70,546,600 are restricted.

Why this is a hot stock

- The company controls 80% of Bankruptcy Claims Fund, Inc., which owns in excess of $8,000,000.00 of the face value of Lehman Brothers claims in the bankruptcy proceeding. The majority of the claims will be administered by the Bank of New York without the need for IOVE to file any formal documents. IOVE did not and does not expect to receive 100% payout on the Capital Trust notes at LEHKQ, LEHLQ, LHHMQ, and LEHNQ. However, IOVE continues to be excited about the prospect of a fair distribution for Capital Trust shareholders.

- IOVE owns 45% of Telecom Tools’ common stock. The patent, for a modification to a tool frequently used in the telecommunications industry, will most likely be submitted to the United States Patent and Trademark Office before the end of the year. Once the patent application is filed, it will be publicly released and IOVE will begin marketing the modification, which may be well received since the modification solves a common problem in the industry.

- 11/23/09 Richwood Eco Ventures, a subsidiary of Accredited Business Consolidators Corp., announced today that it received a commitment for between 310,000 and 600,000 Euros of precut lumber to be exported from Nicaragua over the next six months for home construction. It also received a small order from the same client for finish trim lumber. The client has asked that their identity remain confidential as they are reselling the wood to another customer.

- IOVE will begin the paperwork to obtain a CUSIP for the subsidiary and will subsequently issue a one for one dividend to present shareholders of IOVE. That is, for every share of IOVE, one share of Richwood Eco Ventures would be issued to the IOVE shareholder. The ex date will be set in the next three to six weeks. Richwood Eco Ventures maintains a share structure of 999,999,999 authorized shares. After the issuance of the dividend and the close of the fiscal year, the Company will take the appropriate action necessary to have the financial statements of Richwood Eco Ventures Inc. audited and to register the securities in question with the Securities and Exchange Commission. Once registered, the Company will attempt to secure a market maker for the registered securities so that a trading symbol may be obtained from FINRA.

- The Italian Oven, Inc. a diversified holding corporation, will change its name to Accredited Business Consolidators Corp. to reflect its business model. Prior to the name change, the Company will retire 1,892,100 unrestricted common shares that are held in its treasury. In addition, My Pleasure Limited, the Company’s control group, will retire their 500,000,000 common shares and turn them into non-convertible preferred stock. The preferred stock will have voting rights in the Company, but they can never be turned into common shares or sold on the open market. The Company will reduce its authorized common shares to 450,000,000 from the present 999,999,999.

Contact:
Investor Relations
Accredited Business Consolidators Corp.
ir@accreditedbiz.com
267-864-7737
Fax: 267-371-5168
Twitter: accreditedbiz

www.accreditedbiz.com

Infinity Medical Group, Inc. specializes in servicing medical, dental professionals and specialty healthcare industry in the acquisition of facilities, equipment technology, systemization, branding, containment and development. To the healthcare professions, IMGR enables easy capital equipment acquisition, without personal risk to the healthcare professional.

Company services include:

Turnkey clinic development
Capital acquisition and finance
Software sales and support
Practice management and marketing
HR procurement and Training
Consumer insurance and financing of services

5401 S Kirkman Road
Suite 310
Orlando, FL 32819

Phone: 407-926-0240

www.infinitymedical.com

Beacon Power Corporation designs, develops, and commercializes advanced products and services to support stable and reliable electricity grid operation in North America. The company’s Smart Energy Matrix, which is produced and operational with the Independent System Operator for New England as part of its Alternative Technologies Regulation Pilot Program, is a non-polluting, megawatt-level, utility-grade flywheel-based energy storage system that provides sustainable frequency regulation services. Defense applications The company has completed the design phase for a flywheel energy storage system for satellites capable of achieving maximum theoretical specific energy density. The program was jointly funded by the Air Force Research Lab (AFRL) and the Defense Advanced Research Projects Agency (DARPA). On February 3, 2009, the company entered into a contract with the U.S. Naval Sea Systems Command (NAVSEA) to evaluate the use of flywheel energy storage for multiple shipboard applications. Markets The company’s target markets include New England; California; New York; Mid-Atlantic; Midwest ISO; and Texas. Significant Events In July 2009, Beacon Power Corporation announced that it has completed the connection of a second megawatt (MW) of flywheel energy storage to the New England power grid. This new system doubles the energy storage capacity in operation at Beacon’s Tyngsboro, Massachusetts, headquarters. Competition The company identifies competition from A123.

Why this is a hot stock

- U.S. Department of Energy (DOE) has announced that it has awarded a stimulus grant to Beacon valued at $24 mln, for use in the construction of the Company’s second 20 MW flywheel energy storage plant, to be located in Chicago, Illinois. The grant results from one of Beacon’s two applications for DOE Smart Grid demonstration project funding. The Department made only one award, which was for Beacon’s 20 MW regulation plant. The grant award of $24 mln is for 50% of the project’s estimated cost. DOE will provide further details of the grant conditions in the near future.

- Beacon Power Corporation, a company that designs and develops advanced products and services to support more stable, reliable and efficient electricity grid operation, announced that it will begin construction on the nation’s first full-scale 20-megawatt flywheel frequency regulation plant during the week of November 23rd, at its site in Stephentown, New York.

65 Middlesex Road
Tyngsboro, MA 01879

Phone: 978-694-9121
Fax: 978-694-9127

www.beaconpower.com

ICBS Limited operates as a business development, financial and management consulting company in Canada. The company has acquired a 35% percent interest in Pharmicor Inc. a Quebec based pharmaceutical development company. Pharmicor has developed a nasal formula for the treatment of nasal congestions due to allergies and the Rhinovirus. The company acquired Ramapo Valley Brewery NY, Ramapo Valley Brewery Canada Ltd., and Ramapo Valley Brewery. Along with their Gluten free Honey beer, Ramapo Valley Brewery manufactures Copper, Indian Pale Ale, Porter and seasonal beers. The company offers various services, including business consulting, investment banking, incorporation: canadian or provincial, incorporating in the united states, incorporating offshore, business plan, legal council, acquisitions & mergers, turnaround & restructuring, international corporate placement in North America, immigration visas & programs, governments grants, research & development tax credits, accounting systems, bookkeeping services, auditing services, patents, copyrights, trade marks, taxes, budgets, marketing, IPO’s public offering in the U.S., and reverse mergers. Significant Events The company has formed a partnership with ADNST, Inc., a division of Jabertech Canada Ltd., and has formed ADNST COMMUNICATIONS, LTD.

Why this is a hot stock

- BioSpec Global Solutions Inc., and partner -ICBS Ltd. (OTCPK: ICBT), announced today a new TOG’S 1500 which will combine the technology of the 3000 and 9000 This new equipment will allow expansion into the development of a method for pharmaceutical process water testing along with food testing. “Moving forward with this new TOG’S 1500 will allow the company to develop a wide range of testing procedures for the Pharmaceutical industry.” Said Don Saunders President and CEO BioSpec Global Solutions. “Without constant and proper testing there is always a health concern as water, whether it be drinking water or pharmaceutical grade water can become contaminated.

- The company has entered into talks with a Canadian representative of a major Chinese distribution company. “China is one of the world’s largest markets for our analyzer’s and has one of the worst water situations on the planet” said Don Saunders President and CEO of BioSpec Global Solutions.

- The company will be targeting major food producers in the U.S. and Canada for the use of the TOG’S 9000(TM) which has proceeded in the development of Antibody/antigen multiple discrete optical system (AMUDOS) for the simultaneous analysis of E.coli, in fresh produce.

- The company holds worldwide patents on the TOGS 3000 and 9000 and 1500.

Outstanding Shares
284,005,013 as of Jun 2, 2009

Authorized Shares
500,000,000 as of Oct 1, 2008

Float(shares)
33,977,044 as of Jun 1, 2009

ICBS Ltd.
1310 Green Avenue
Suite 730
Montreal, QC H3Z 2B2
Canada

Phone: 514-932-4402
Fax: 514-932-6755
www.icbs.ca

Wellstar International, Inc., through its subsidiary, Trillennium Medical Imaging, Inc., engages in developing and licensing the use of advanced thermal imaging technology in the consumer healthcare and veterinary markets in the United States. The company places cameras in hospitals, clinical, and care facilities based on its infrared technology and software. Its technology enables a diagnostic screening procedure for early breast cancer detection; differential diagnosis of pain dysfunctions, such as reflex sympathetic dystrophy, neuromuscular skeletal syndromes, and neurological disorders; and detection of pressure ulcers; deep tissue injuries; and bed sores, as well as orthopedic applications. Wellstar International markets its products to university research centers, hospitals, multidisciplinary physician practices, pain centers, care facilities, home health care, and rehabilitation centers. The company was founded in 1997 and is based in Holland, Ohio.

Trillennium Medical Imaging, Inc. (TMI) is dedicated to placing cameras for a monthly charge in hospitals, clinical and long care facilities throughout the United States. The company’s current competitive advantage is derived from the state of the art technology of the camera and software it is utilizing, combined with an intimate knowledge and relationships in the markets. It plans to grow in these markets by expanding its imaging capabilities by the constant acquisitions of new imaging technologies.

The TMI Infrared Technology and software is approved by the FDA as an Adjunctive Diagnostic screening procedure for early breast cancer detection, differential diagnosis of pain dysfunctions, (such as Reflex Sympathetic Dystrophy, Neuromuscular Skeletal Syndromes and Neurological disorders), detection of pressure ulcers, deep tissue injuries, and bed sores, as well as orthopedic applications. This screening modality provides a differential diagnosis to justify additional screening procedures to ensure successful patient outcome assessment. Thermal Imaging is a low cost, non-contact, non-radioactive diagnostic screening procedure designed for clinical evaluation. In addition thermal imaging provides an ability to track the progress of therapies being utilized in a low cost, non-invasive manner.

The TMI Infrared Technology fills a need that currently exists in diagnostic medicine today. Thermal imaging provides information that is specific to the physiological and functional activity in the body. This information becomes invaluable in that conventional diagnostic screening utilizes tests such as X-Ray, MRI and CT Scans. All aspects of these tests are concerned with the anatomical and structural problems of the body. Many problems arise from not combining both diagnostic modalities of structure and physiology, in that people are missed diagnosed and considered healthy and well when the physiological information provides an earlier outcome or risk assessment of future health predictors than the structural modalities.

Major markets such as University Research Centers, hospitals, multidisciplinary physician practices, pain centers, long term care facilities, home health care, and rehabilitation centers support the need for this type of screening modality.

In summary, Trillennium Medical Imaging has created an innovative new business model that gives it early market advantage.

Why this is a hot stock

- Trillennium Medical Imaging sees the future of infrared imaging moving to critical positions in early phase disease detection and monitoring. Although currently not a diagnostic modality, infrared analysis still provides key information in health monitoring. The development of objective data analysis and proof of efficacy will catapult infrared detection to key positions and prominence. Trillennium’s completed research project conducted at Duke University for early detection of tissue breakdown, provides the initial data demonstrating the TMI Systems ability to detect damage prior to visible evidence. This capability – in a non-contact device – will save patients from potential disabling conditions, as well as generate a sizeable cost-savings in health care.

- Trillennium Medical has begun investigating the use of infrared detection in early stage pressure ulcer development. Trillennium is proposing a unique approach for early detection of tissue changes that will significantly impact the wound care market. TMI is in the initial phase for design and application of a new imaging device that incorporates software and data collection that is separate and apart from its current clinical markets.

- Trillennium Medical Imaging will be ideally positioned to provide a cost-effective, non-contact method to identify the presence of early or existing tissue damage. The next step for TMI is to implement the system within the marketplace with a Beta Test. TMI believes that the Beta Test will begin the early part of 2010 as we are currently in discussions.

- Each year the government spends on average over $3 billion on wound treatment and care for pressure sores and bedsores. Insurance companies pay out millions annually for this same treatment, directly affecting premiums to increase annually for healthcare facilities. Inflationary effects add to this escalation.

Wellstar International Inc.
6911 Pilliod Road
Holland, OH 43528

Phone: 419-865-0069
Fax: 419-867-0829
www.wellstar.us

CompuSonics Video Corporation – CPVD.PK annouced the following news release on Monday October 19, 2009 causing its stock price to jump from a LOW of $0.002 to a HIGH of $0.054 for a 2700% one day gain.

CompuSonics Video Corporation Announces Major Development with Patent Portfolio
By: PR Newswire | 19 Oct 2009 | 10:36 AM ET

FARMINGTON HILLS, Mich., Oct 19, 2009 /PRNewswire via COMTEX/ — FARMINGTON HILLS, Mich., Oct. 19 /PRNewswire-FirstCall/ — CompuSonics Video Corporation (OTC: CPVD), which engages in the ownership and licensing of various patents in the fields of digitalization and compression of audio and video files, announced today that the company has reached an out-of-court settlement regarding the company’s patent portfolio. For several years, we believed our patents have been used by 50 companies or more widespread. The companies are among the world’s largest electronics firms in the semiconductor, communications equipment, computer hardware, electronic instruments, computer peripherals, scientific and technical instruments, video storage and computer networks. The use of our patents is essential to the operation of thousands of products. From the time the patents were issued to date, the company estimates that over $100 billion worth of digitalization and compression of audio and video files, have made use of CompuSonics technology worldwide. CompuSonics Video Corporation is considering many options to bring back shareholder value, a few of them that are being discussed are a cash dividend per share with no restrictions and a stock buy-back program in the open market. Below is a list of the company’s patent portfolio. Some of the patents listed have expired, but during the time they were active companies have violated CPVD’s rights. Further details will be released soon.

Then came this release below, causing its share price to close at $0.0057 (-74.67%) on Tuesday October 20, 2009.

/K I L L — CompuSonics Video Corporation/
By: PR Newswire | 20 Oct 2009 | 12:59 PM ET

Journalists and other readers should disregard the news release, CompuSonics Video Corporation Announces Major Development with Patent Portfolio (OTC: CPVD – News), issued Oct. 19, 2009 over PR Newswire, as CompuSonics Video Corporation neither issued nor authorized any news release. The information contained in this Oct. 19, 2009 news release regarding a settlement is erroneous.

Talk about a wild pink sheet company. Is this legal? Did someone release insider information? What will happen to investors who bought the stock for $0.05 a share? Is this some kind of pump and dump scam? Who is behind all this? Is the SEC going to do anything about it? Only time will tell.

1115 Orlando Avenue
Roseville, CA 95661-5247

Phone: 916-745-0900
Fax: 916-745-0999
www.solarpowerinc.net

Solar Power, Inc. engages in the sale, installation, and integration of solar modules, balance-of-system components, and integration services, including system design and installation. The company offers photovoltaic (PV) systems, solar panels and related hardware and cable, wire and mechanical assemblies. Products and Services The company’s products in general are built-up through 4 stages of production: Wafers, Cells, Modules, and Systems. Wafers: A crystalline silicon wafer is a flat piece of crystalline silicon that can be processed into a solar cell. Wafers are usually square or square with rounded corners. A typical size is 152 millimeters by 152 millimeters. Cells: A solar cell is a device made from a wafer that converts sunlight into electricity by means of a process known as the photovoltaic effect. Solar cells produce approximately 3.5 watts of power each. Modules: A solar module is an assembly of solar cells that have been electrically interconnected and laminated in a physically durable and weather-tight package. A typical solar module can produce from 20 to 300 watts of power and range in size from 2 to 25 square feet. Its typical commercial module would range from 180 to 220 watts. Systems: A solar system is an assembly of one or more solar modules that have been physically mounted and electrically interconnected by cables, meters and inverters to produce electricity. Typical residential on-grid systems produce 2,000 to 6,000 watts of power. Subsidiaries The company’s business is conducted through its wholly-owned subsidiaries, SPIC, Inc. (SPIC), Yes! Solar, Inc. (YES), Yes! Construction Services, Inc. (YCS), IAS-HK and IAS Shenzhen. SPIC and YCS are engaged in the business of design, sales and installation of photovoltaic (PV) solar systems for commercial, industrial and residential markets. YCS is also a company-owned franchise territory. YES is engaged in the sale and administration of its franchise operations. IAS-HK is engaged in sales of its cable, wire and mechanical assemblies business. IAS Shenzhen is engaged in manufacturing its solar modules, its balance of solar system products and continues to be engaged in its legacy cable, wire and mechanical assemblies business. Customers The company designs, integrates and installs photovoltaic power systems to various customers, including private residential owners, production home builders and commercial facilities. It also manufactures solar panels which it not only uses in its own installations, but sells to other integrators in the Asian and European markets. Competition The company’s major systems integration competitors include Sun Power Corporation; SPG Solar; Akeena Solar; and Sun Edison. Its manufacturing competitors include multinational corporations, such as BP Solar; Kyocera Corporation; Mitsubishi; Solar World AG; Sharp Corporation; Sun Power Corporation; and Sanyo Corporation. History Solar Power, Inc. was founded in 2005.

Why this is a hot stock

- Friday September 18, 2009 Solar Power, Inc. (“SPI”) (OTCBB: SOPW) has been named Fastest Growing Company in the Sacramento region for 2009. The award was accepted by Solar Power Inc.’s CEO Steve Kircher at a ceremony hosted Tuesday night by The Sacramento Business Journal. The award, which is presented annually to the Sacramento region’s fastest growing company from a large group of contenders, was won by SPI for the second consecutive year.

- Tuesday October 6, 2009 Solar Power, Inc. announced a $14,000,000 Private Placement from institutional and accredited investors.

- Monday October 19, 2009 Solar Power, Inc. announced today that it has executed a second supply agreement with Bayer and Raach, a German solar installation company serving the residential and commercial market segments throughout Germany and Southern Europe. The supply agreement calls for SPI to provide 1.5 megawatts of SPI’s 200-watt modules to meet initial-phase requirements for a 5-megawatt system Bayer and Raach is installing in Bavaria. The system will be built in phases over 2009 and 2010, ultimately calling for a total of 5 megawatts of SPI’s 200-watt modules which are top ranked for performance with the California Energy Commission.

501 Santa Monica Boulevard
Suite 700
Santa Monica, CA 90401

Phone: 310-432-4090
Fax: 310-432-4098
www.corcell.com

Cord Blood America, Inc., through its subsidiaries, provides private cord blood stem cell preservation services to families. The company also focuses on collecting, processing and preserving peripheral blood and adipose tissue stem cells allowing individuals to privately preserve their stem cells for potential future use in stem cell therapy. In addition it creates direct response television and radio advertising campaigns, including media placement and commercial production. Subsidiaries The company’s subsidiaries include Cord Partners, CorCell Co. Inc., CorCell Ltd., (Cord), CBA Professional Services, Inc. D/B/A BodyCells, Inc. (BodyCells), CBA Properties, Inc. (Properties), and Career Channel Inc, D/B/A Rainmakers International (Rain). CORD Services Provided By Cord Cord’s customers are typically expectant parents who choose to collect and store umbilical cord blood at the birth of their child for potential use in a stem cell transplant at a later date for that child or for another family member. Through partnering with Progenitor Cell Therapy, LLC (PCT), Cord is able to provide services to collect, test, process and preserve umbilical cord blood. Collection: The company provides a kit that contains all of the materials necessary for collecting the newborn’s umbilical cord blood at birth and packaging the unit for transportation. The kit also provides for collecting a maternal blood sample for later testing. Full-Time Physician and Customer Support: The company provides 24-hour consulting services to customers, as well as to physicians and labor and delivery personnel, providing any instruction necessary on the collection of the cord blood. Transportation: The company manages all logistics for transporting the cord blood unit to its centralized facility immediately following birth. Comprehensive Testing: At the laboratory, the cord blood sample is tested for stem cell concentration levels and blood type. The cord blood sample and the maternal blood sample are also tested for infectious diseases. The company reports these results to both the mother and her doctor. Cord Blood Preservation: After processing and testing, the cord blood unit is cryogenically frozen in a controlled manner and stored in liquid nitrogen for potential future use. The company’s cord blood units are tested, processed and stored at, Progenitor Cell Therapy, LLC (PCT), in Hackensack, New Jersey. BodyCells is a developmental stage company in the business of collecting, processing and preserving peripheral blood and adipose tissue stem cells that allows individuals to privately preserve their stem cells for potential future use in stem cell therapy. RAIN Rain operates in the business of advertising. Rain offers its advertising and direct marketing customers a range of services, including the placement of advertising in television and radio outlets; the production of advertising content, including television commercials, and radio copy; and advertising and marketing consulting services relating to the customer’s marketing campaign. In performing its advertising agency services, Rain outsources commercial production services to third party production companies. Rain’s advertising clients are typically small companies for whom its range of services include, in addition to the placement of advertising, a range of consulting services which can include assistance in program, but helping the client to design or develop the particular product or service, determine the appropriate market and design and implement an overall marketing program and strategy. Significant Events The company has signed an agreement with a marketing affiliate for expansion of its services into Panama, Bermuda and Aruba. The marketing arrangement is intended to target hospitals and obstetricians/gynecologists in those areas. Competition The company’s competitors include Integrated Media, Last Second Media, Media Associates, RevShare, Mercury Media, ChoicePoint Precision Marketing, and E&M Advertising. History Cord Blood America, Inc. was founded in 2003.

Why this is a hot stock

- New Corporate headquarters and cryogenic research and storage laboratory in Las Vegas will open the first week of October 2009. “We anticipate processing of stem cells in the new lab to commence sometime in the fourth quarter of 2009. We are confident that this new facility will assist Cord Blood America to become a giant in the cryogenic storage sector,” said Mr. Schissler.

- The new facility will significantly reduce the cost of sales while increasing gross profits, because we no longer have to outsource the storage and because of its proximity to one of the nation’s busiest airports.

- Company reduced its debt by a total of $3.7 million in the third quarter of 2009. Total debt eliminated in 2009 is $8.7 million.

Ingen Technologies, Inc.
35193 Avenue “A”
Suite-C
Yucaipa, CA 92399
United States

Phone: 800-259-9622
www.ingen-tech.com

Ingen Technologies, Inc., a medical device manufacturer, engages in the development, marketing, and distribution of medical technologies and products with applications in the respiratory device markets and the medical diagnostics market, as well as in emergency response, aviation, military and consumer markets. Products Ingen Technologies manufactures the medical devices Oxyview and OxyAlert, which are products designed for the respiratory patient market in the USA and abroad. Oxyview and OxyAlert provide the respiratory clinicians, including pulmonologists, respiratory therapists and patient care technicians a medical product that provides assurance and safety to home oxygen patients and hospitalized patients while monitoring oxygen flow during oxygen therapy. Patients using portable oxygen concentrators, home oxygen concentrators, liquid oxygen and oxygen gas can use Oxyview and OxyAlert to improve their oxygen delivery. Oxyview is a Class-I medical device as classified with the US Food and Drug Administration as an in-line oxygen flow meter that is powered by the flow of oxygen and requires no batteries. Oxyview provides a visual cue to the patient or administrator, indicating the continuous flow and volume of oxygen during therapy. It allows the user to be sure that they are receiving the proper oxygen level and alerts them if adjustments need to be made. This device would simplify the oxygen therapy process. Oxyview is reusable, requires no batteries, works all the time in any position with all liquid or gas oxygen delivery systems, and installs anywhere below the cannula nearest the patient where oxygen flow matters the most. In addition to Oxyview, the company is set up to begin selling a natural energy drink referred to as PogaMoonga. This product is a natural drink processed from pomegranate, aloe vera and the leaves and seeds of the moringa tree. This product provides oxygen therapy patients, and consumers with a way to naturally increase their energy levels. OxyAlert is a multi-patented wireless digital pressure gauge with hand-remote, and audio/visual safety warning device used on stationary and remote oxygen delivery devices, such as concentrators and cylinders; used by patients, hospitals, commercial aircraft, military transport, and fire and safety equipment. GasAlert is a commercial consumer product using the same technology as OxyAlert. This device would monitor and detect gas flow for home appliances, such as ovens, washer, dryer, refrigerator and outdoor plumbed barbeques. GasAlert uses the same technology as OxyAlert, and its application is directed towards determining gas leaks. GasAlert would be marketed upon the US Food and Drug Administration’s classification and acceptance of OxyAlert. The Secure Balance product is a private-label product that includes a vestibular function testing system and balance therapy system. The vestibular (referencing organs in the inner ear) function testing system is manufactured by Interacoustics LTD. in Denmark and is referred to as the VNG. This is an accepted method among physicians to provide diagnostic testing of the inner-ear and central nervous system, in order to provide qualitative results that determine a diagnosis of a patients balance problem. This system is used to provide therapy to patients with balance problems through the use of computerized clinical software tools. The company’s Secure Balance program provides balance testing/assessment equipment, education and training about balance and fall prevention to physicians and clinicians worldwide. Competition The company’s products compete with the Liter-Meter manufactured by Erie Medical, Inc., and the Rotameter manufactured by King Instruments. History Ingen Technologies, Inc. was founded in 1999.

Why this is a hot stock

- Ingen has interested acquirers according to the Pacific Pearl Group Inc., and company management has agreed to hold the buy-out price of no less than 10 cents a share,” stated Thomas J. Neavitt, Chief Financial Officer.

- On November 18, 2009, Emergo Group will introduce the new Oxyview Nasal Cannula at MEDICA in Germany. MEDICA is the center of attraction for all those involved in the health care industry. More than 135,000 visitors from well over 100 countries are expected to again obtain information on all the current and future trends in in-patient and out-patient care at this annual event. With its extensive ancillary program, numerous special events, two major congresses and the largest product display in the industry, MEDICA is the hub of the medical trade.

- On January 25, 2010, the Emergo Group will introduce the new Oxyview Nasal Cannula at Arab Health. The Arab Health Exhibition & Congress is the largest healthcare exhibition in the Middle East, and the second largest in the world. Arab Health is viewed as a must-attend global event in the healthcare calendar. Established 35 years ago, it provides a platform for the world’s leading manufacturers, wholesalers and distributors to meet the medical and scientific community in the Middle East and beyond.

- Mr. Sand refused to consider any reverse split now or in the future. Mr. Sand said that he is confident that the company cash reserve and increased revenues would support a share buy-back program for the shareholders. Mr. Sand further stated his concern with the past reverse splits, and he said that it would be unfair to the shareholders of this company to consider or effect any more reverse splits. Mr. Sand reminded the shareholders that he has converted his unpaid salary to shares over the past 5 years, and he was a shareholder as well who endured the greatest loss of personal capital with the reverse splits effected in the past.

- The designated Chinese patent application no. 200710005067.4 was officially issued and published on July 1, 2009 for the cannula gas flow meter referred to as “Oxyview”. The company’s pending patents in Japan, Canada, and the European Communities are expected to issue in 2010.

- As a part of improving product quality in large production, and reducing material and production costs to be more competitive in the respiratory marketplace, the company has received a proposal from a leading respiratory equipment manufacturer based in Pomona-California to manufacture both the Oxyview and the Oxyview Nasal Cannula at 50% of the original costs from its current manufacturer and supplier. “Now that we are selling our respiratory products, and sales have escalated, we must reduce our cost of goods sold in order to increase our profit margins and decrease the costs to our dealers and buyers. This change will give the company a stronger foot-hold in the market. We have a proprietary product and there is nothing in the marketplace that can compete with our device. We have gained support for all sectors of our industry, inclusive of leading respiratory equipment manufacturers, clinical foundations and more important, our shareholders,” stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

- The Oxyview Nasal Cannula is available in various models for adult, pediatric and infant. Each age group can purchase the 0-6 liter/minute or the new “low flow” 0-3 liter/minute Oxyview Nasal Cannula. Included are discounts for purchasing the 10-Pack, 50-Pack or 100-Pack containers.

5307 NW 35th Court
Plantation, FL 33309
United States

Phone: 954-581-9800
Fax: 954-581-0555
www.imds.com

Imaging Diagnostic Systems, Inc., a development stage medical technology company, engages in the development and testing of a Computed Tomography Laser Breast Imaging System for detecting breast cancer (CT Laser Mammography or CTLM). The company is in the process of commercializing the CTLM in certain international markets. CTLM system The CTLM system is a CT-like scanner, but its energy source is a laser beam. CTLM is a new imaging modality offering the potential of molecular functional imaging, which can visualize the process of angiogenesis which may be used to distinguish between benign and malignant tissue. The CTLM is being marketed as an adjunct to mammography to provide the radiologist with additional information to manage the clinical case. The company intends to develop its technology into a family of related products. The CTLM system laser diodes can stimulate fluorescent light emissions when used in conjunction with compounds. When an appropriate fluorescent compound has been introduced into the blood, areas with an abundance of blood vessels, that is the angiogenesis associated with a tumor, may retain a higher concentration of the fluorescent compound. Laser Imager for Lab Animals The company’s Laser Imager for Lab Animals ‘LILA’ program is an optical helical micro-CT scanner in a third-generation configuration. The system was designed to image various compounds, especially green fluorescent protein, derived from the DNA of jellyfish. The LILA scanner is targeted at pharmaceutical developers and researchers who monitor cancer growth and who use multimodality small animal imaging in their clinical research. Markets The company markets CTLM to centers performing x-ray mammography. CTLM Laser Mammography Systems are installed in the following countries: Italy, Germany, Poland, the Czech Republic, the Peoples Republic of China, Malaysia and the United Arab Emirates. Sales and Marketing The company has a major commercial presence in the Peoples Republic of China (PRC). Significant Events In September 2009, Imaging Diagnostic Systems Inc. announced the sale of another CT Laser Mammography system in Asia. The system, which was sold to and installed at the Katherine Women’s Health Center in Malaysia, is being used in patient examinations. The Women’s Health Center would also serve as a training and demonstration site for future customers. Competition The company’s competitors include Advanced Research Technologies, Inc. and Philips Medical Systems. History Imaging Diagnostic Systems, Inc. was founded in 1993.

Why this is a hot stock

- Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The Computed Tomography Laser Mammography (CTLM®) system uses lasers to image the breast in a non-invasive procedure. Unlike x-ray mammography, CTLM images blood hemoglobin and the process of neoangiogenesis or new vessel formation which is often associated with breast cancer.

- CT laser breast imaging is part of the emerging field of optical imaging.

- In a study of over 100 women, including 30 with breast cancer, optical imaging increased sensitivity and specificity of breast cancer detection by more than 90% (Britton Chance, Molecular Imaging, Vol. 2 #2)

- CTLM may provide a brighter future for cancer patients due to earlier diagnosis and treatment. Early visualization of tumors in the evolving process will lead to breast sparing surgery and less trauma to the patient.

One Penn Plaza
Suite 1612
New York, NY 10119
United States

Phone: 212-994-5374
Fax: 646-572-6336
www.greenshift.com

GreenShift Corporation develops and commercializes clean technologies that facilitate the use of natural resources. The company owns four corn oil extraction facilities that are located in Oshkosh, Wisconsin, Medina, New York, Marion, Indiana, and Riga, Michigan. It has also installed one facility in Albion, Michigan. It has the long-term right to buy the oil extracted from the Albion facility. The company also owns a 10 million gallon per year biodiesel refinery located in Adrian, Michigan and an oilseed crushing facility in Culbertson, Montana. The company’s segments include Equipment & Technology Sales; Culinary Oil Production & Sales; and Biofuels Production & Sales. Competition The company competes with Archer Daniels Midland Corporation, Bunge Limited, Cargill, Tyson, and Conoco Phillips. History The company was founded in 1984. It was formerly known as GS CleanTech Corporation and changed its name to GreenShift Corporation in 2008.

Why this is a hot stock

- On Wednesday October 14, 2009, GreenShift Corporation announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,601,858, titled “Method of Processing Ethanol Byproducts and Related Subsystems” (the ’858 Patent) for the extraction of corn oil to GS CleanTech Corporation, a wholly-owned subsidiary of GreenShift.

- GreenShift’s patented and patent-pending corn oil extraction technologies enable GreenShift and its licensees to “drill” into the back-end of first generation corn ethanol plants to tap into a new reserve of inedible crude corn oil with an estimated industry-wide output of about 20 million barrels per year. This corn oil is a valuable second generation feedstock for use in the production of biodiesel and renewable diesel – advanced carbon-neutral liquid fuels, thereby enhancing total fuel production from corn and increasing ethanol plant profits.

- GreenShift’s portfolio of patented and patent-pending extraction technologies can cost-effectively extract most of this corn oil, thereby increasing biofuel yields per bushel of corn by 7% while reducing the energy consumption and greenhouse gas (“GHG”) intensity of corn ethanol production by an estimated 21% and 29%, respectively.

- Tuesday October 20, 2009 GreenShift Corporation announced today that the U.S. Patent and Trademark Office issued notice that pending patent number 11/688,435 will be issued as U.S. Patent No. 7,608,729, titled “Method of Freeing the Bound Oil Present in Whole Stillage and Thin Stillage” (the ’729 Patent) on October 27, 2009 to GS CleanTech Corporation, a wholly-owned subsidiary of GreenShift.

Hard to Treat Diseases Inc. engages in the research, development, purchase, sale, and marketing of biological vaccines in China. It offers various vaccines, such as hepatitis A, hepatitis B, varicella, poliomyelitis, influenza virus, DTaP combined, meningococcal, and MMR combined vaccines. The company also provides other biological products, including refined tetanus antitoxin and cerebroprotein hydrolysate for injection. In addition, it offers API and injection products comprising meropenem for injection and Imipenem/Cilastatin sodium for injection. The company is based in Shenzhen, China.

Why this is a hot stock

- On Monday September 14, 2009 Mellow Hope completed the clinical trial of Influenza A (H1N1) Vaccine (Split Virion). The company received the clinical approval from the State Food and Drug Administration (SFDA) http://eng.sfda.gov.cn/eng. Production will be started shortly.

- According to health minister Chen Zhu “China will be able to produce enough influenza A(H1N1) vaccines for 65 million people by the end of this year.” (65 million is only about 5% of China’s 1.3 billion, population)

BioElectronics Corporation develops and markets drug-free anti-inflammatory patches. The company’s products include ActiPatch Therapy, a dermal drug-free, painless, and pulsed energy patch with an embedded battery operated microchip that delivers pulsed electromagnetic frequency therapies to accelerate healing of soft tissue injuries. Its technology provides pulsed electromagnetic energy therapy that is used to reduce swelling, relieve pain, and enhance the healing of post-surgical incisions, chronic wounds, and orthopedic conditions. The company markets its products in the United States, Canada, and Europe. BioElectronics Corporation sells its products to wholesale distributors, as well as directly to hospitals and clinics. Recent Highlights

• BioElectronics has retained industry leader, Schulberg MediaWorks as its marketing partner. Work on the DRTV spots has already begun with initial airing expected within 60 days. Initially, the Canadian and selected other English speaking markets will be targeted, but the U.S. market will also be heavily targeted once FDA clearance is received.

• Indendent analyst Carrie Snyder, places a target price on BIEL shares of between $0.30 and $0.50, should expected FDA clearances be granted.

• Clinical Results — David G. Genecov, M.D. FACS FAAP, provided preliminary data on a heel and foot pain study showing strong efficacy and 100% safety using the ActiPatch device. The study also showed study participants were able to significantly reduce their use of acetaminophen, the active ingredient in Tylenol, and non-steroidal anti-inflammatory drugs (NSAIDs). Considering the recent FDA panel recommendation relating to acetaminophen usage, these results are highly significant.

• Clinical Studies and FDA Filings — Clinical studies in the areas of breast augmentation, Cesarean section, Uveitis, and several areas of surgical recovery are quickly coming to a close with data expected over the coming months. With the data provided by the Genecov study, the management team plans to accelerate its FDA 510(k) pre-marketing clearance filing for general musculoskeletal complaints designed to lead to over-the-counter approval. In addition, the Company will soon submit an additional application of 510(k) pre-marketing clearance for general surgical recovery.

• International Distribution Expansion — International distribution relationships continue to advance at a rapid rate. The Company announced it will soon be entering the German and Spanish markets, which will augment other international markets, particularly the Italian, Korean and Canadian markets, which are already showing revenue acceleration. Several Asian distribution partnership agreements are currently being negotiated.

• Financials — Management indicated that the financial position of the Company has improved dramatically over the past few months. Further payments have been made on convertible debentures with balances dropping from more than $910,000 one year ago to less than $50,000 today. Elimination of all convertible debenture balances is likely over the coming weeks. BioElectronics is maintaining very strong gross margins and tight expense controls, resulting in the Company operating at near breakeven levels. The working capital position at the Company has also significantly improved. The recent U.S. Government Export-Import Bank guarantee is expected to further improve the working capital position.

• Company Priorities — The priorities for BioElectronics remain the completion of clinical trials, FDA submissions, expansion of international distribution, and the further development of our patented, drug-free brands: Allay, ActiPatch and RecoveryRx.

• BioElectronics Receives Groundbreaking Patent – PEMF technology has been proven safe and effective in hundreds of peer-reviewed scientific studies. Up until now, however, PEMF devices have been very expensive large devices and usually based in clinical settings such as clinics or hospitals. Through the use of advanced micro-circuitry the engineers at BioElectronics have shrunk this technology into a wafer-thin device that can be worn directly on the skin to relieve pain, swelling and speed healing.

Why this is a hot stock

- BioElectronics Announces Worldwide DRTV Strategy to Launch DRTV Campaigns in South America, Canada and Europe.

- BioElectronics Technology More Effective Than Extra Strength Tylenol(R) in Reducing Muscle Soreness. In Clinical Study ActiPatch Proved 50 Percent More Effective Than Acetaminophen.

- Monday October 19, 2009 BioElectronics Corp. announced the initial results from the pilot section of its ongoing acetaminophen comparison study. The study, which is expected to be complete during early November, compares the effects of ActiPatch? Therapy to acetaminophen in the form of Extra Strength Tylenol? for the treatment of delayed onset muscle soreness (DOMS).

- Wednesday September 30, 2009 BioElectronics Corp. announced the availability of a new product targeted at the $10 billion dollar veterinary care market, the HealFast Therapy PetPatch(TM).

- Biel is waiting on FDA approval for its Allay Patch anticipated 2nd half of August while planning on filing 2 more FDA 510k submissions. Per last conference call on July 28th, 2009 , 2 institutional investors have invested in Biel which is very rare and a real honor for companies traded on the Pink Sheets.

BioElectronics Corporation
4539 Metropolitan City
Frederick, MD 21704
Phone: 301-644-3906
Fax: 301-644-3937
www.bielcorp.com

Cell Therapeutics, a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its pipeline includes Pixantrone: for non-Hodgkin’s lymphoma, Brostallicin: for the treatment of sarcoma, and OPAXIO: for the potential treatment of non-small ovarian cancer.

Recent Highlights

• Completed the submission of the pixantrone NDA to the FDA to treatrelapsed or refractory aggressive non-Hodgkin’s lymphoma (NHL). CTI requested priority review of the pixantrone NDA which, if granted, could lead to an approval decision from the FDA in the fourth quarter of 2009.

• Reduced outstanding debt by $52.9 million, representing 44.5% of outstanding debt, through exchange offers completed in June 2009, resulting in an estimated savings in future annual interest expense of approximately $3.3 million.

• Added to the Russell 3000 , Russell 2000 and Russell Global Indexes.

• Raised $43.8 million in gross proceeds in connection with financing transactions in the second quarter of 2009, and an additional $41.7 million in proceeds, net of underwriting discount, in connection with an underwritten offering of common stock and warrants in July 2009.

Why this is a hot stock

-Institutions are pooring in, new institutional holdings recently added. You can view more info at http://www.mffais.com/ctic

BioCentric Energy Holdings, Inc. is dedicated to the development of new technologies as well as acquiring and fostering companies with innovative technologies designed to provide unique and effective green energy solutions for the 21st century. Along with the cultivation of important relationships and partnerships with synergistic entities, BioCentric Energy has devoted substantial time and effort in research and development in order to bring a range of innovative green alternatives to the marketplace. It offers biodiesel, ethanol, Pyrolysis processed bio oil, biogas, char, oxygenated diesel, and electricity. The company represents biodiesel producers in the United States. BioCentric Energy Incorporated is based in Huntington Beach, California.

Why this is a hot stock

- The company is expected to finalize the agreement this week with the publicly traded development company.

- Contract and licensing talks with Korean municipalities are still moving forward; announcements are expected shortly.

- Contract and Licensing talks with China and surrounding areas are at LOI stage and are expected to be finalized next month.

- The company has made an offer to purchase the San Juan Capistrano facility from Zion Bank; an announcement is expected later this month.

- Discussions with one of the largest poultry companies in the US are moving forward as BioCentric has developed an enhanced cost effective ALGAE strain for poultry foods.

- The company has finalized the agreement for the production of a company owned and operated 10 acre closed loop ALGAE Farm in Death Valley, Nevada. Production is expected to start later this year.

- The company is currently in the process of negotiating for a 10 acre land parcel within the San Juan Capistrano area for the production of a company owned and operated ALGAE farm.

- Merger agreement with a fully reporting company and soon to listed on OTCBB.